UK Preclinical Cro Market Size & Outlook, 2023-2030
UK preclinical cro market, 2018-2030 (US$M)
Related Markets
UK preclinical cro market highlights
- The UK preclinical cro market generated a revenue of USD 450.6 million in 2023 and is expected to reach USD 748.8 million by 2030.
- The UK market is expected to grow at a CAGR of 7.5% from 2024 to 2030.
- In terms of segment, toxicology testing was the largest revenue generating service in 2023.
- Bioanalysis and DMPK studies is the most lucrative service segment registering the fastest growth during the forecast period.
Preclinical cro market data book summary
| Market revenue in 2023 | USD 450.6 million |
| Market revenue in 2030 | USD 748.8 million |
| Growth rate | 7.5% (CAGR from 2023 to 2030) |
| Largest segment | Toxicology testing |
| Fastest growing segment | Bioanalysis and DMPK studies |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Bioanalysis and DMPK studies, Toxicology Testing, Compound Management, Chemistry, Safety Pharmacology |
| Key market players worldwide | Eurofins Scientific SE, Icon PLC, Wuxi AppTec Co Ltd, Medpace Holdings Inc, Charles River Laboratories International Inc, Thermo Fisher Scientific Inc, Intertek Group PLC, Labcorp Holdings Inc, Crown Bioscience, SGA |
Other key industry trends
- In terms of revenue, UK accounted for 7.9% of the global preclinical cro market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, UK preclinical cro market is projected to lead the regional market in terms of revenue in 2030.
- UK is the fastest growing regional market in Europe and is projected to reach USD 748.8 million by 2030.
Toxicology testing was the largest segment with a revenue share of 26.14% in 2023. Horizon Databook has segmented the UK preclinical cro market based on bioanalysis and dmpk studies, toxicology testing, compound management, chemistry, safety pharmacology covering the revenue growth of each sub-segment from 2018 to 2030.
The UK is a major hub for large pharmaceutical companies with a key focus on R&D activities and clinical trials to minimize the burden of various infectious diseases. According to gov.uk, in 2020, Life Science Competitiveness Indicators (LSCIs) presented the UK’s R&D expenditure, which showed that the government’s budget for health R&D was USD 3.44 billion (GBP 2. billion) in 2020, accounting for 0.12% of the country’s GDP.
Besides, industry conducted pharmaceutical R&D valued at over USD 6.37 billion (GBP 5 billion) in 2020. Increased healthcare R&D is one of the major factors responsible for the dominance of this country in the European preclinical trial outsourcing market. In March 2022, the UK government allocated over USD 347 million for healthcare research in order to improve the research activities in the country.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Preclinical CRO Market Scope
Preclinical CRO Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
UK preclinical cro market size, by service, 2018-2030 (US$M)
UK Preclinical CRO Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
